In June 2022, Alnylam® Pharmaceuticals announced that another siRNA that reduces TTR protein production, AMVUTTRATM (vutrisiran), received the FDA approval, followed by the EMA approval in September 2022, for the treatment of hATTR amyloidosis with polyneuropathy69. Here, TTR is linked to amyloidosis.